| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |